New combo therapy aims to tackle Hard-to-Treat gut tumors
NCT ID NCT07185672
First seen Jun 24, 2026 · Last updated Jun 24, 2026
Summary
This Phase 3 trial tests whether adding chemotherapy (capecitabine and temozolomide) to standard radiation therapy (PRRT) helps people with advanced neuroendocrine tumors of the stomach, intestines, or pancreas that show high activity on FDG PET scans. The study will enroll 162 adults whose tumors are well-differentiated but FDG-avid, a sign of more aggressive disease. The main goal is to see if the combination delays tumor growth or death compared to PRRT alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEUROENDOCRINE NEOPLASIA'S (NENS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)
RECRUITINGNavi Mumbai, Maharashtra, 410210, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tata Memorial Hospital, Mumbai, India
RECRUITINGMumbai, Maharashtra, 400012, India
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Lutetium-177 PRRT (radiation therapy) plus capecitabine and temozolomide (chemotherapy)
What this could lead to
If successful, this combination could improve progression-free survival for patients with aggressive neuroendocrine tumors that show FDG activity on scans.
What could go wrong
This is a Phase 3 trial but still experimental; adding chemotherapy to PRRT may increase side effects without clear benefit. Results may not apply to all NET subtypes.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.